Inclusion Criteria:

- Histologically or cytologically confirmed metastatic melanoma

- Measurable disease

- 18 years of age or older

- ECOG performance status of 0, 1 or 2

- Normal organ and marrow function as outlined in the protocol

- Women of childbearing potential must have a negative serum pregnancy test within 7
days of the first administration of study treatment and must be willing to use two
methods of contraception during the study and for 3 months after last study drug
administration

- Clinically euthyroid

- Biopsiable disease: Disease must be in the opinion of the treating investigator
biopsiable such that there are minimal risks involved

Exclusion Criteria:

- Chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who
have not recovered from adverse events due to agents administered more than 4 weeks
earlier

- May not be receiving any other study agents, anti-cancer therapy or radiation therapy

- Known brain metastases or any history of brain metastases

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to LBH589

- Concomitant use of drugs with a risk of causing torsades de pointes

- Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer

- Patients who will need valproic acid for any medical condition during the study or
within 5 days prior to first LBH589 treatment

- Impaired cardiac function

- Uncontrolled hypertension

- Patients with unresolved diarrhea grade 2 or greater

- Impairment of the gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of oral LBH589

- Pregnant or breastfeeding women

- Individuals with a history of a different malignancy are ineligible except for the
following circumstances: disease-free for at least 5 years and are deemed by the
investigator to be at low risk for recurrence of that malignancy; individuals with
the following cancers are eligible if diagnosed and treated within the past 5 years:
cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.

- Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C

- Patients with any significant history of non-compliance to medical regimens or with
inability to grant a reliable informed consent

- Uncontrolled and/or severe intercurrent illness including, but not limited to ongoing
or active infection or psychiatric illness/social situations that would limit
compliance with study requirements